# Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)

> **NCT01159847** · PHASE1,PHASE2 · COMPLETED · sponsor: **European Foundation for the Study of Diabetes** · enrollment: 30 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** sitagliptin
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT01159847
- **Lead sponsor:** European Foundation for the Study of Diabetes
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2012-07
- **Final completion:** 2012-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-07-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01159847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01159847, "Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01159847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*